Pyxis Oncology Q1 net loss narrows to $3.3M; PYX-201 data on track for fall 2024

Pyxis Oncology, Inc.

2024-Q1 EPS reported -$0.06 revenue$16,146,000

Revenue of $16.1M from Novartis royalty settlement; net loss $3.3M ($0.06/sh) vs $19.2M ($0.54/sh) YoY.
Cash & investments $158.5M; runway into 2H 2026; raised ~$60.8M via ATM, private placement, and Novartis deal.
PYX-201 Phase 1: 42 patients dosed; 16 more planned; results including efficacy expected fall 2024.
PYX-106 Phase 1: 24 subjects dosed; preliminary data anticipated in 2H 2024.
Appointed Stephen Worsley as Senior Vice President, Chief Business Officer.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Pyxis Oncology, Inc. reported financial results for the quarter ended March 31, 2024.

Period: the quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and provided a corporate update.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Pyxis Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-059093

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.